Sandoz loses challenge to patent on Amgen’s $5.2B autoimmune drug, may appeal to Supreme Court
A federal appeals court upheld two key patents covering Amgen's Enbrel, thus further preventing Novartis' generics unit from launching its biosimilar. However, an analyst wrote that the probability of Sandoz overturning the decision is low.